Nurix Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Nurix Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 117% in 3 years, but profit fell: $185 less profit per $100 of extra sales. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-15.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$185Sales grew 117% in 3 years, but profit fell: $185 less profit per $100 of extra sales.
Lower than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+117% / +65%In 3 years sales changed by +117% while total assets changed by +65%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-88.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+19%Cash, after subtracting all debt, equals 19% of its market value (net cash).
Higher than 62% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Nurix Therapeutics, Inc. owes $0.25 for every $1 it owns. Nurix Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Nov 2025.
P/E ratio
10.5Investors pay $10.5 for every $1 of Nurix Therapeutics, Inc.'s yearly profit, lower than 81% of Healthcare companies in United States.
P/B ratio
6.92The share price is 6.92 times Nurix Therapeutics, Inc.'s book value per share, higher than 80% of Healthcare companies in United States.
Market cap
$2.8 BThe total market value of all of Nurix Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 79% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$403 MWhat Nurix Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 May 2026).
Book value per share
$3.69Net worth divided by the number of shares. The share price of $25.51 is 6.9 times this, which is the P/B above.
Return on equity (ROE)
44.0%Nurix Therapeutics, Inc. earned 44.0% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
Owes vs Owns
0.25×Nurix Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Dividend yield
NoneNurix Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+54%Revenue rose 54% in the year to Nov 2025, and grew 30% a year on average over 3 years.
Profit growth
LossNurix Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-314.9%Nurix Therapeutics, Inc. lost $315 for every $100 of revenue.
Cash vs debt
Net cashNurix Therapeutics, Inc. held $537 M more cash than debt (net cash) at Nov 2025.
Questions
What is Nurix Therapeutics, Inc.'s P/E ratio?
Investors pay $10.5 for every $1 of Nurix Therapeutics, Inc.'s yearly profit, lower than 81% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Nurix Therapeutics, Inc.: $2.8 B ÷ $403 M (31 May 2026) = 6.9.
What is Nurix Therapeutics, Inc.'s return on equity?
Nurix Therapeutics, Inc. earned 44.0% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
How much does Nurix Therapeutics, Inc. owe compared with what it owns?
Nurix Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Does Nurix Therapeutics, Inc. pay a dividend?
No. Nurix Therapeutics, Inc. does not currently pay a dividend.
Is Nurix Therapeutics, Inc.'s revenue growing?
Revenue rose 54% in the year to Nov 2025, and grew 30% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.